Early treatment and a longer life - new Orfadin formats meet new patient needs - Seite 2

Orfadin is approved in the EU and several other countries for the treatment of patients with confirmed diagnosis of hereditary tyrosinaemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. HT-1 is a progressive disease where the body lacks the ability to break down the amino acid tyrosine. Without treatment, HT-1 is ultimately fatal. Orfadin, together with the appropriate diet, is an essential part of effective HT-1 treatment.  

---

About Orfadin
Orfadin (nitisinone) blocks the breakdown of tyrosine, thereby reducing the amount of toxic by-products in the body. People with Hereditary Tyrosinaemia type-1 (HT-1) have problems breaking down an amino acid called tyrosine. Toxic by-products are formed and accumulate in the body, which can cause liver failure, renal dysfunction and neurological complications. In the most common form of the disease, symptoms arise within the first six months of the child's life. Patients must maintain a special diet in combination with Orfadin treatment as tyrosine remains in the body. Approximately 1,000 persons are identified as living with HT-1 today.

Orfadin is a proprietary product and is developed by and marketed globally by Sobi.

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations
Oskar Bosson, Head of Communications
T: [phone]
[e-mail]                                                                            

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
T: [phone], [phone], [phone]